Tyra Biosciences, Inc. TYRA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.31M-39.6% | -$33.83M-32.3% | -$29.87M-24.4% | -$28.1M-50.2% | -$28.15M-54.7% | ||
| $138K-3.5% | $132K-8.3% | $131K+3.1% | $140K+11.1% | $143K+17.2% | ||
| $7.85M+22.2% | $7.63M+13.8% | $7.58M+0.1% | $6.38M+44.6% | $6.42M+56.1% | ||
| $1.2M+427% | $2.16M— | $2.07M— | -$491K— | -$365K+94.7% | ||
| -$32.57M-27.9% | -$23.62M-20.6% | -$22.38M-25.0% | -$23.68M-131% | -$25.46M-15.6% | ||
| $88K+529% | $57K+850% | $39K-25.0% | $31K-93.4% | $14K-89.7% | ||
| -$120.24M-475% | $34.38M— | —— | $20.87M+114% | $32.03M+77.2% | ||
| $147.85M— | —— | —— | —— | $0— | ||
| $160.38M+7,233% | $4.68M+563% | $647K-12.9% | $583K+56.3% | $2.19M-98.9% | ||
| $7.57M-13.6% | —— | -$36.54M-930% | —— | $8.76M-95.5% | ||
| $2.44M-8.6% | $0-100% | $1.89M-6.3% | $928K+124% | $2.67M+6,102% | ||
| $17K-22.7% | $17K-26.1% | $19K-29.6% | $25K-13.8% | $22K-79.0% | ||
| $12.53M+473% | $4.68M+563% | $647K-12.9% | $583K-6.6% | $2.19M+352% | ||
| $20K— | $43K— | $25K+174% | $0-100% | $0-100% | ||
| —— | $60.25K— | $60.25K— | $60.25K— | $60.25K— | ||
| $0-100% | —— | —— | —— | $3K-82.4% | ||
| -$32.66M-28.2% | -$23.68M-20.8% | -$22.42M-24.9% | -$23.71M-121% | -$25.47M-14.9% | ||
| -$32.66M-28.2% | -$23.68M-20.8% | -$22.42M-24.9% | -$23.71M-121% | -$25.47M-14.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tyra Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Tyra Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.